Patents by Inventor Stig Jonas Bostrom
Stig Jonas Bostrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230348363Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: ApplicationFiled: February 22, 2023Publication date: November 2, 2023Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM, Giulia Bergonzini, Henrik Graden, Lars Johan Andreas Ulander
-
Patent number: 11667602Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: GrantFiled: December 7, 2021Date of Patent: June 6, 2023Assignees: AstraZeneca AB, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kenneth Lars Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, Yasuki Niwa, Masakazu Fujio, Hans Fredrik Bergström, Stig Jonas Boström
-
Publication number: 20230078576Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where A, U, V, W, X, Y, Z, R1, R2, R3, R4 and R5 have the meanings defined herein. Such compounds are modulators of RXFP1 and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions including heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The specification further relates to compositions comprising such compounds, intermediates useful in processes for preparing such compounds, and processes for preparing such compounds using such intermediates.Type: ApplicationFiled: December 7, 2021Publication date: March 16, 2023Inventors: Kenneth Lars GRANBERG, Shigeki SAKAMAKI, Ryuichi FUCHIGAMI, Yasuki NIWA, Masakazu FUJIO, Hans Fredrik BERGSTRÖM, Stig Jonas BOSTRÖM
-
Patent number: 8067584Abstract: Compounds of formula: (1) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia are described. Processes for their manufacture and pharmaceutical compositions containing them are also described.Type: GrantFiled: February 23, 2004Date of Patent: November 29, 2011Assignee: Albireo ABInventors: Ingemar Starke, Suzanne Alenfalk, Mats Peter Nordberg, Mikael Ulf Johan Dahlstrom, Stig Jonas Bostrom, Malin Anita Lemurell, Andreas Christer Wallberg
-
Patent number: 7342019Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are attaType: GrantFiled: December 18, 2002Date of Patent: March 11, 2008Assignee: AstraZeneca ABInventors: Anna Ingrid Kristina Berggren, Stig Jonas Boström, Stig Thomas Elebring, Peter Greasley, Emma Terricabras, Johan Michael Wilstermann
-
Patent number: 7238684Abstract: The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.Type: GrantFiled: April 23, 2003Date of Patent: July 3, 2007Assignee: AstraZeneca ABInventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, Mats Peter Nordberg, Suzanne Alenfalk, Andreas Christer Wallberg, Stig Jonas Bostrom
-
Patent number: 7192946Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia.Type: GrantFiled: August 30, 2002Date of Patent: March 20, 2007Assignee: AstraZeneca ABInventors: Ingemar Starke, Mikael Ulf Johan Dahlstrom, David Blomberg, Suzanne Alenfalk, Peter Nordberg, Andreas Christer Wallberg, Stig Jonas Bostrom
-
Publication number: 20050143368Abstract: The present invention relates to compounds of formula (1): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acceptable salts, solvates, solvates or such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.Type: ApplicationFiled: April 23, 2003Publication date: June 30, 2005Inventors: Ingemar Starke, Mikael, Ulf, Johan Dahlstrom, Mats, Peter Nordberg, Suzanne Alenfalk, Andreas, Christer Wallberg, Stig, Jonas Bostrom
-
Publication number: 20050032808Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1 and R2 independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)s in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)t Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1 represents H and R2 is as defined above; or R1 and R2 together with the nitrogen atom to which they are attaType: ApplicationFiled: December 18, 2002Publication date: February 10, 2005Inventors: Anna Berggren, Stig Jonas Bostrom, Stig Elebring, Peter Greasley, Emma Terricabras, Johan Wilstermann
-
Publication number: 20040254160Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.Type: ApplicationFiled: July 23, 2004Publication date: December 16, 2004Inventors: Ingemar Starke, Mikael ulf Johan Dahlstrom, David Blomberg, Suzanne Alenfalk, Peter Nordberg, Andreas Christer Wallberg, Stig Jonas Bostrom